相似文献
1
When MicroRNAs Meet RNA Editing in Cancer: A Nucleotide Change Can Make a Difference.
Bioessays. 2018 Feb;40(2). doi: 10.1002/bies.201700188. Epub 2017 Dec 27.
2
Adenosine-to-Inosine RNA Editing Enzyme ADAR and microRNAs.
Methods Mol Biol. 2021;2181:83-95. doi: 10.1007/978-1-0716-0787-9_6.
3
ADAR enzyme and miRNA story: a nucleotide that can make the difference.
Int J Mol Sci. 2013 Nov 19;14(11):22796-816. doi: 10.3390/ijms141122796.
4
A-to-I RNA editing and cancer: from pathology to basic science.
RNA Biol. 2008 Jul-Sep;5(3):135-9. doi: 10.4161/rna.5.3.6739. Epub 2008 Jul 5.
5
In cancer, A-to-I RNA editing can be the driver, the passenger, or the mechanic.
Drug Resist Updat. 2017 May;32:16-22. doi: 10.1016/j.drup.2017.09.001. Epub 2017 Oct 4.
6
The adaptive potential of RNA editing-mediated miRNA-retargeting in cancer.
Biochim Biophys Acta Gene Regul Mech. 2019 Mar;1862(3):291-300. doi: 10.1016/j.bbagrm.2018.12.007. Epub 2018 Dec 31.
7
Base-pairing probability in the microRNA stem region affects the binding and editing specificity of human A-to-I editing enzymes ADAR1-p110 and ADAR2.
RNA Biol. 2018;15(7):976-989. doi: 10.1080/15476286.2018.1486658. Epub 2018 Jul 24.
8
A-to-I RNA editing as a tuner of noncoding RNAs in cancer.
Cancer Lett. 2020 Dec 1;494:88-93. doi: 10.1016/j.canlet.2020.08.004. Epub 2020 Aug 19.
9
A-to-I RNA Editing Up-regulates Human Dihydrofolate Reductase in Breast Cancer.
J Biol Chem. 2017 Mar 24;292(12):4873-4884. doi: 10.1074/jbc.M117.775684. Epub 2017 Feb 10.
10
MicroRNA Editing Detection and Function: A Combined In Silico and Experimental Approach for the Identification and Validation of Putative Oncogenic Targets.
Methods Mol Biol. 2021;2181:253-267. doi: 10.1007/978-1-0716-0787-9_15.
引用本文的文献
1
Identification of microRNA editing sites in clear cell renal cell carcinoma.
Sci Rep. 2023 Sep 13;13(1):15117. doi: 10.1038/s41598-023-42302-y.
2
Adenosine deaminase acting on RNA 1 (ADAR1) as crucial regulators in cardiovascular diseases: structures, pathogenesis, and potential therapeutic approach.
Front Pharmacol. 2023 Aug 17;14:1194884. doi: 10.3389/fphar.2023.1194884. eCollection 2023.
3
MiRNAs in Hematopoiesis and Acute Lymphoblastic Leukemia.
Int J Mol Sci. 2023 Mar 12;24(6):5436. doi: 10.3390/ijms24065436.
4
The cellular and KSHV A-to-I RNA editome in primary effusion lymphoma and its role in the viral lifecycle.
Nat Commun. 2023 Mar 13;14(1):1367. doi: 10.1038/s41467-023-37105-8.
5
RNA Editing in Glioma as a Sexually Dimorphic Prognostic Factor That Affects mRNA Abundance in Fatty Acid Metabolism and Inflammation Pathways.
Cells. 2022 Apr 5;11(7):1231. doi: 10.3390/cells11071231.
6
MicroRNA editing patterns in Huntington's disease.
Sci Rep. 2022 Feb 24;12(1):3173. doi: 10.1038/s41598-022-06970-6.
7
Epitranscriptomics: A New Layer of microRNA Regulation in Cancer.
Cancers (Basel). 2021 Jul 5;13(13):3372. doi: 10.3390/cancers13133372.
8
MiRNA post-transcriptional modification dynamics in T cell activation.
iScience. 2021 May 12;24(6):102530. doi: 10.1016/j.isci.2021.102530. eCollection 2021 Jun 25.
9
Bisulphite miRNA-seq reveals widespread CpG and non-CpG 5-(hydroxy)methyl-Cytosine in human microRNAs.
RNA Biol. 2021 Dec;18(12):2226-2235. doi: 10.1080/15476286.2021.1927423. Epub 2021 Jun 7.
10
Genome-Wide Characterization of RNA Editing Sites in Primary Gastric Adenocarcinoma through RNA-seq Data Analysis.
Int J Genomics. 2020 Dec 18;2020:6493963. doi: 10.1155/2020/6493963. eCollection 2020.
本文引用的文献
1
Rewriting the transcriptome: adenosine-to-inosine RNA editing by ADARs.
Genome Biol. 2017 Oct 30;18(1):205. doi: 10.1186/s13059-017-1347-3.
2
A-to-I editing in human miRNAs is enriched in seed sequence, influenced by sequence contexts and significantly hypoedited in glioblastoma multiforme.
Sci Rep. 2017 May 26;7(1):2466. doi: 10.1038/s41598-017-02397-6.
3
Systematic characterization of A-to-I RNA editing hotspots in microRNAs across human cancers.
Genome Res. 2017 Jul;27(7):1112-1125. doi: 10.1101/gr.219741.116. Epub 2017 Apr 14.
4
ADAR1 and MicroRNA; A Hidden Crosstalk in Cancer.
Int J Mol Sci. 2017 Apr 11;18(4):799. doi: 10.3390/ijms18040799.
5
A-to-I RNA Editing Up-regulates Human Dihydrofolate Reductase in Breast Cancer.
J Biol Chem. 2017 Mar 24;292(12):4873-4884. doi: 10.1074/jbc.M117.775684. Epub 2017 Feb 10.
6
Functions of the RNA Editing Enzyme ADAR1 and Their Relevance to Human Diseases.
Genes (Basel). 2016 Dec 17;7(12):129. doi: 10.3390/genes7120129.
7
The double-domain cytidine deaminase APOBEC3G is a cellular site-specific RNA editing enzyme.
Sci Rep. 2016 Dec 15;6:39100. doi: 10.1038/srep39100.
8
LNCediting: a database for functional effects of RNA editing in lncRNAs.
Nucleic Acids Res. 2017 Jan 4;45(D1):D79-D84. doi: 10.1093/nar/gkw835. Epub 2016 Sep 19.
9
The dual role of complement in cancer and its implication in anti-tumor therapy.
Ann Transl Med. 2016 Jul;4(14):265. doi: 10.21037/atm.2016.06.26.
10
ADAR1 Activation Drives Leukemia Stem Cell Self-Renewal by Impairing Let-7 Biogenesis.
Cell Stem Cell. 2016 Aug 4;19(2):177-191. doi: 10.1016/j.stem.2016.05.004. Epub 2016 Jun 9.
Zotero 插件